Spyros Papapetropoulos insider trades: Lipocine (LPCN) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Spyros reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 22, 2022 | LPCN | ↑ Buy | 21,739 | $0.47 | $10K | Direct | Nov 28, 2022 (6d) |
| Nov 18, 2022 | VIGL | ↓ Sell | 300 | $14.00 | $4K | Direct | Nov 22, 2022 (4d) |
| May 3, 2022 | VIGL | ↑ Buy | 4,000 | $3.40 | $14K | Direct | May 4, 2022 (1d) |
| Mar 11, 2021 | ADMS | ↑ Buy | 5,975 | $5.06 | $30K | Direct | Mar 15, 2021 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LPCN insiders
Open-market trades in the last 12 months
About Spyros Papapetropoulos's insider trades
Spyros Papapetropoulos is a director at Lipocine (LPCN). Since Mar 11, 2021, Spyros has reported 3 open-market purchases worth $54K and 1 sale worth $4K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (10 filings), option exercises (1 filing), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LPCN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.